BioNTech SE (BNTX) Cash from Discontinued Operations (2019 - 2025)

BioNTech SE (BNTX) reported Cash from Discontinued Operations of 912681309.82 for Q3 2025, up 230.08% on a YoY basis from 276506427.74 in Q3 2024, and up 450.36% sequentially from 165832094.29 in Q2 2025.

BioNTech SE (BNTX) Cash from Discontinued Operations (2019 - 2025) Analysis & Trends

BioNTech SE (BNTX) has 7 years of Cash from Discontinued Operations data on file, last reported at 912681309.82 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 BioNTech SE 22.13 Bn 22.13 Bn 668.28 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 912.68 Mn
Sep 30, 2025 912.68 Mn
Jun 30, 2025 165.83 Mn
Jun 30, 2025 165.83 Mn
Mar 31, 2025 -821.21 Mn
Mar 31, 2025 -821.21 Mn
Sep 30, 2024 -701.65 Mn
Sep 30, 2024 -701.65 Mn
Jun 30, 2024 1.75 Bn
Jun 30, 2024 1.75 Bn
Mar 31, 2024 -344.70 Mn
Mar 31, 2024 -344.70 Mn
Sep 30, 2023 883.06 Mn
Sep 30, 2023 883.06 Mn
Jun 30, 2023 4.78 Bn
Jun 30, 2023 4.78 Bn
Mar 31, 2023 -727.08 Mn
Mar 31, 2023 -727.08 Mn
Jun 30, 2022 4.18 Bn
Jun 30, 2022 4.18 Bn